ArticleImmuno-oncology technology2026

Combining circulating inflammatory proteins and thymidine kinase activity to predict survival in melanoma patients receiving immune checkpoint inhibitors.

S Egyhazi Brage et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.